Full-Time

Executive Director

Therapeutics Translational Research

Confirmed live in the last 24 hours

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

Biotechnology
Healthcare

Senior, Expert

Cambridge, MA, USA

This role is expected to be in office 70% of the time with flexibility to work from home up to 30%.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary

You match the following Moderna's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • PhD, MD, or MD/PhD in Immunology, Oncology, or a related field with 15+ years of industry experience, including 3+ years in senior leadership roles.
  • 1+ years of direct experience in early clinical trials.
  • Demonstrated expertise in Translational Research and/or Medicine, with deep oncology experience across preclinical and early clinical development phases and experience running internal labs.
  • Proven ability to lead and grow diverse, multidisciplinary teams, fostering collaboration and innovation.
  • Comprehensive knowledge of immunological assays and biomarkers, molecular pathology, and sequencing. Expertise with stage-appropriate CDx development, including Regulatory guidance.
  • Strong leadership presence with experience influencing cross-functional stakeholders, including senior leadership, to drive strategic alignment.
  • Track record of developing and executing high-impact translational strategies with measurable program outcomes.
  • Outstanding organizational, communication, and decision-making skills, with the ability to manage multiple complex initiatives simultaneously.
  • Entrepreneurial mindset with a passion for delivering on ambitious goals in a fast-paced, dynamic environment.
Responsibilities
  • Set, drive and communicate the overarching vision and strategy for Therapeutics Translational Research to support Moderna’s therapeutics pipeline, spanning oncology and other therapeutic areas such as autoimmunity.
  • Lead the development of translational strategies as early as in discovery, incorporating patient identification assays, disease monitoring, and proof-of-mechanism and/or pharmacodynamic readouts, to generate key value-driving and decision-making data.
  • Oversee and expand key translational capabilities, including molecular pathology, sequencing technologies, and immunological assay optimization, to support robust decision-making and product differentiation.
  • Deliver stage-appropriate and fit-for-purpose plans and assays for patient identification and pharmacodynamics assays for transfer to internal Clinical Biomarkers team, including the development of stage-appropriate companion diagnostics (CDx) technology to accelerate clinical entry and advancement.
  • Manage a high-performing team of scientists and leaders, fostering a culture of innovation, collaboration, and operational excellence. Prioritize and allocate resources across the team to meet portfolio needs.
  • Partner with key cross-functional collaborators, such as Translational Medicine and Clinical Biomarkers, to ensure seamless assay development, optimization, and execution for clinical programs.
  • Represent Translational Research at senior leadership forums, governance, and external engagements, communicating key updates and aligning on strategic priorities.
  • Drive innovative translational insights and learnings from clinical studies back into Research to inform and shape subsequent technology, therapeutics discovery, and early pipeline efforts.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial molecule that provides instructions for cells to produce proteins necessary for various biological functions. Their approach involves creating a new class of medicines that leverage mRNA to potentially transform how drugs are discovered, developed, and manufactured. Unlike traditional pharmaceuticals, which often rely on proteins or small molecules, Moderna's mRNA-based therapies aim to instruct the body to produce its own therapeutic proteins. This unique method sets Moderna apart from competitors, as it opens up new possibilities for treating diseases and improving patient outcomes. The company's goal is to harness the power of mRNA to create effective treatments that can significantly enhance the quality of life for patients.

Company Size

5,001-10,000

Company Stage

IPO

Total Funding

$6.5B

Headquarters

Cambridge, Massachusetts

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna secured a $590 million contract for bird flu vaccine development.
  • The company is expanding its mRNA applications to rare diseases and cancer.
  • Moderna's cost reduction efforts aim to save nearly $1 billion by 2025.

What critics are saying

  • Increased competition from BioNTech and Pfizer may impact Moderna's market share.
  • Potential regulatory delays could affect Moderna's growth and revenue targets.
  • Fluctuating COVID-19 vaccine demand creates uncertainty in Moderna's sales forecasts.

What makes Moderna unique

  • Moderna is pioneering mRNA technology for a new class of medicines.
  • The company has a strong late-stage pipeline with multiple product approvals anticipated.
  • Moderna's mRNA platform enables rapid development of vaccines and therapeutics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

401(k) Company Match

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

2%

2 year growth

4%
PharmiWeb
Feb 14th, 2025
Moderna Reports Fourth Quarter And Fiscal Year 2024 Financial Results And Provides Business Updates

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizingReports full-year revenues of $3.2 billion, GAAP net loss of $(3.6) billion and GAAP diluted EPS of $(9.28)Expects 2025 revenue range of $1.5 to 2.5 billion andending cash balance of approximately $6 billionSubmitted three investigational mRNA products for regulatory approval, including Moderna's next-generation COVID vaccine, RSV vaccine for high-risk adults aged 18 to 59, and flu/COVID combination vaccineCAMBRIDGE, MA / ACCESS Newswire / February 14, 2025 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the fourth quarter and fiscal year 2024."We have made progress in 2024 across our late-stage pipeline and cost reduction efforts. Our team successfully filed three Biologics License Applications in the final months of the year and reduced our costs by 27 percent compared to 2023," said Stéphane Bancel, Chief Executive Officer of Moderna. "In 2025, we remain focused on driving sales, delivering up to 10 product approvals through 2027, and expanding cost efficiencies across our business. By the end of 2025, we aim to remove nearly $1 billion in costs. With strong momentum in our late-stage pipeline, we anticipate multiple approvals starting this year, along with key Phase 3 readouts that will support our long-term growth."Recent progress includes:Commercial UpdatesModerna is entering 2025 with two approved products, Spikevax® and mRESVIA®.COVID-19: The Company reported $923 million in Spikevax® sales in the fourth quarter of 2024, which includes $244 million of U.S

The Scotsman
Feb 13th, 2025
Scotland's Life Sciences Conference & Awards 2025: Uniting industry leaders to shape the future

Scotland's thriving life sciences sector, a key driver of innovation and economic growth, is set to take centre stage in 2025 with the launch of Scotland's Life Sciences Conference, sponsored by Moderna.

PharmiWeb
Jan 29th, 2025
Moderna To Report Fourth Quarter And Full Year 2024 Financial Results On Friday, February 14, 2025

CAMBRIDGE, MA / ACCESS Newswire / January 29, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 14, 2025 to report its fourth quarter and full year 2024 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.The archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaModerna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines

PharmiWeb
Jan 24th, 2025
Moderna Awarded Tender For The Supply Of Its Mrna Covid-19 Vaccine In The European Union

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formatsCAMBRIDGE, MA / ACCESS Newswire / January 24, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine in the European Union (EU), Norway and North Macedonia. Under the resulting agreement, 17 participating countries can access Moderna's mRNA COVID-19 vaccine for up to four years."This agreement presents an opportunity for Moderna to support and strengthen national COVID-19 vaccination campaigns across participating countries," said Chantal Friebertshäuser, Senior Vice President, General Manager - Europe & Middle-East, Moderna. "Diversity of supply and availability of vaccine formats such as pre-filled syringes are vital to help increase vaccination rates and enhance vaccination campaign efficiency, ultimately strengthening health security."Under the agreement, Moderna can provide its COVID-19 vaccine in several formats, including prefilled syringes. This is the preferred product presentation for healthcare providers as it can decrease the risk of administration errors and save time, which may ultimately improve vaccination campaign efficiency.In September 2024, the European Commission (EC) granted marketing authorization for an updated formulation of Moderna's COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 variant JN.1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older.About ModernaModerna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone

Managed Healthcare Executive
Jan 22nd, 2025
Moderna Awarded $590 Million for Bird Flu Vaccine Development

The development of avian influenza vaccines is the main priority amid rising cases in the United States.